Pyrimidine derivatives for the treatment of viral infections
US-10420767-B2 · Sep 24, 2019 · US
Pyrimidine prodrugs for the treatment of viral infections and further diseases
US2020031779A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020031779-A1 |
| Application number | US-201716338256-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 28, 2017 |
| Priority date | Sep 29, 2016 |
| Publication date | Jan 30, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
First claim
Opening claim text (preview).
1 . A compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein R 1A is selected from hydrogen, a substituted or unsubstituted C 1-3 alkyl, heterocycle, or a substituted or unsubstituted phosphoramidate, R 1B is selected from hydrogen, a substituted or unsubstituted C 1-3 alkyl, heterocycle, or a substituted or unsubstituted phosphoramidate, with the exception that R 1A and R 1B are not both hydrogen, and wherein R 2 is a C 1-8 alkyl, which is optionally substituted by a hydroxyl group. 2 . A compound according to claim 1 wherein R 1A or R 1B are a substituted or unsubstituted phosphoramidate and wherein R 2 is a C 1-6 alkyl preferably substituted by a hydroxyl group. 3 . A compound according to claim 1 wherein R 1A or R 1B are methyl and wherein R 2 is a C 6 -alkyl substituted by a hydroxyl group. 4 . A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers. 5 . (canceled) 6 . (canceled) 7 . A compound according to claim 1 wherein R 1A and R 1B are a substituted or unsubstituted phosphoramidate and wherein R 2 is a C 1-6 alkyl preferably substituted by a hydroxyl group. 8 . A compound according to claim 1 wherein R 1A and R 1B are methyl and wherein R 2 is a C 6 -alkyl substituted by a hydroxyl group. 9 . A pharmaceutical composition comprising a compound according to claim 2 together with one or more pharmaceutically acceptable excipients, diluents or carriers. 10 . A pharmaceutical composition comprising a compound according to claim 7 together with one or more pharmaceutically acceptable excipients, diluents or carriers. 11 . A method for treating a virus infection, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 4 in an effective amount to treat the virus infection. 12 . A method for treating according to claim 11 , wherein the virus infection is a hepatitis B infection. 13 . A method for treating an immune disorder, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 4 in an effective amount to treat the immune disorder. 14 . A method for treating cancer, comprising administering to a subject in need thereof the pharmaceutical composition according to claim 4 in an effective amount to treat the cancer.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020031779A1 cover?
- This invention relates to pyrimidine prodrug derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy.
- Who is the assignee on this patent?
- Janssen Sciences Ireland Unlimited Co
- What technology area does this patent fall under?
- Primary CPC classification C07D239/48. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jan 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).